ARTEMISMED.NS Stock Analysis
AR
Avoid
Based on Eyestock quantitative analysis, ARTEMISMED.NS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Market cap $B
0.025
Dividend yield
0.49 %
Shares outstanding
136.88 B
Artemis Medicare Services Ltd. provides health care services. The company employs 1,937 full-time employees The company went IPO on 2020-01-23. The firm is expertized in the spectrum of advanced medical and surgical interventions, a mix of inpatient and outpatient services. The firm offers treatment facilities for various medical conditions under various specialties, which include allergy and immunology, blood (haematology), bones, muscles and joints (orthopaedics), brain, spine and nervous system, cancer (oncology), circulatory (vascular), dermatology, digestive (gastroenterology), endocrine, diabetes and metabolismheart (cardiology), infectious diseases, kidneys (renal), lung (pulmonary), mouth, teeth and face (oral and maxillofacial), obstetrics and gynaecology, psychiatry, rheumatology (arthritis and joint disease), surgery and urology. The firm's subsidiary includes Artemis Cardiac Care Private Limited.